New Saliva and Blood Tests Are Ending the Decade-Long Delay in Endometriosis Diagnosis

Endometriosis is one of the most common, yet chronically misunderstood, conditions in women's health. Affecting approximately one in ten reproductive-age women globally, the disease occurs when tissue similar to the lining of the uterus grows outside the womb, attaching to ovaries, fallopian tubes, and the pelvic lining. For millions, it causes debilitating chronic pain, severe fatigue, and infertility. Despite its prevalence and severity, the medical system has historically struggled to identify it promptly. On average, patients endure a grueling diagnostic odyssey lasting between seven and ten years, a delay that allows the disease to progress unchecked and leaves countless women feeling dismissed or gaslighted about their own pain.[1][2]

The primary driver of this decade-long delay is the medical bottleneck of the diagnostic process itself. For decades, the undisputed gold standard for confirming endometriosis has been a laparoscopy—a surgical procedure requiring general anesthesia, incisions in the abdomen, and specialized gynecological surgeons. Because the procedure is invasive, expensive, and carries inherent surgical risks, doctors often delay recommending it until a patient has exhausted years of hormonal therapies and pain management strategies. This reliance on the operating room to simply confirm an illness has created a systemic barrier to care, leaving patients in diagnostic limbo.[1][6]

However, the landscape of women's health is currently undergoing a profound transformation. Over the course of 2025 and early 2026, a wave of breakthrough non-invasive diagnostic tools has moved rapidly from laboratory research into clinical application. Leveraging advances in artificial intelligence, molecular biology, and genomic sequencing, researchers have developed highly accurate tests that use saliva, blood, and menstrual fluid to detect the disease. This shift from surgical exploration to clinical "liquid biopsies" represents a fundamental paradigm change, promising to reduce diagnosis times from nearly a decade to a matter of days.[1][6]

At the forefront of this diagnostic revolution is a saliva-based test developed by the French biotechnology company Ziwig. Known as the Ziwig Endotest, the diagnostic tool represents the first commercially available, non-invasive method of its kind. Rather than looking for physical lesions, the test analyzes a patient's saliva for specific molecular signatures. It is built on the discovery that endometriosis alters the expression of microRNAs—small, non-coding RNA molecules that regulate gene expression and are shed into bodily fluids.[1][3][7]

The mechanism behind the Ziwig Endotest relies heavily on artificial intelligence. The test sequences the saliva sample to analyze a complex signature of 109 specific microRNAs. By feeding this data into an AI model trained on thousands of clinical profiles, the system can identify the presence of endometriosis with remarkable precision. In massive multicenter validation studies, the saliva test demonstrated an accuracy rate of 96.6 percent and a specificity of over 94 percent, effectively matching or exceeding the diagnostic certainty of conventional imaging for early-stage disease.[1][3][7]

The clinical rollout of the saliva test has accelerated dramatically. In early 2025, French health authorities issued an Innovation Funding decree to fast-track reimbursement for the Ziwig Endotest, making it accessible to 25,000 patients across 80 medical centers in France. The test is already available via prescription in the United Kingdom, Germany, Switzerland, and several Middle Eastern nations, though out-of-pocket costs—currently around £800 in the UK—remain a hurdle. The company is actively pursuing FDA approval to bring the technology to the United States market.[1][3][7]

While saliva testing gains regulatory traction in Europe, parallel breakthroughs are occurring in blood-based diagnostics. Australian medical technology firm Proteomics International is preparing to launch PromarkerEndo, a blood test that analyzes a panel of ten distinct protein biomarkers. By measuring these specific proteins, the test generates a predictive risk score for endometriosis. In recent validation data presented at the World Congress on Endometriosis, the blood test demonstrated 83 percent sensitivity and 95 percent specificity, offering a rapid screening tool that could help general practitioners prioritize patients for specialist referrals.[1][6]

Another highly promising blood assay, HerResolve by HerAnova, takes a multi-omics approach. This test combines data from three microRNAs, three protein biomarkers, and steroid hormone levels, processing the information through an AI algorithm that also factors in the patient's age and body mass index. Recent multicenter trials showed the HerResolve test achieving 94.4 percent accuracy. The company is currently preparing its submission to the US Food and Drug Administration, targeting a regulatory green light by late 2026.[1]

The push for early detection has also yielded critical discoveries for younger patients. At the Yale School of Medicine, researchers recently identified a novel microRNA signature specifically in adolescents and young adults that correlates with the earliest stages of endometriosis. Because over half of patients report their symptoms beginning during adolescence, this discovery is vital. Detecting the disease through a simple blood draw before it causes irreversible scarring or compromises fertility could fundamentally alter the life trajectory of young women who are currently told their severe cramps are normal.[4]

Beyond saliva and peripheral blood, scientists are unlocking the diagnostic potential of menstrual fluid. In a landmark study, researchers in Spain and France successfully isolated menstrual blood-derived stem cells to detect the disease. Unlike previous methods that required culturing cells in a lab—which alters their biological makeup—this new approach analyzes freshly isolated cells using DNA methylation profiling. This technique examines the chemical tags that turn genes on or off, achieving an 81 percent accuracy rate in distinguishing patients with endometriosis.[5]

The use of menstrual blood is particularly exciting for researchers because it provides direct access to the very cells believed to drive lesion formation. By analyzing the molecular signals in menstrual effluent, clinicians can gain a deeper understanding of how the disease is behaving in a specific patient. This could eventually allow doctors to stratify patients based on their unique disease profile, paving the way for highly targeted, personalized therapies rather than a one-size-fits-all hormonal treatment.[5]

Advancements are not limited to fluid analysis; medical imaging is also experiencing a breakthrough. A recent clinical trial in the United Kingdom demonstrated the potential of an experimental radiotracer called maraciclatide. When infused into a patient, this tracer specifically binds to tissue that is actively creating new blood vessels—a hallmark of growing endometriosis lesions. During a Spect-CT scan, the radiotracer causes the hidden endometrial tissue to literally light up on the monitor, revealing superficial peritoneal endometriosis that traditional ultrasounds and MRIs frequently miss.[2]

The biological mechanism uniting all these non-invasive tests is the recognition of endometriosis as a systemic, inflammatory condition rather than just a localized pelvic issue. Ectopic endometrial tissue interacts with the body's immune system, shedding unique proteins, inflammatory cytokines, and microRNAs into the bloodstream. Because these molecules circulate systemically, they eventually appear in saliva and other fluids, acting as molecular breadcrumbs that advanced sequencing technologies can now reliably detect and decode.[1][4]

The clinical implications of replacing the surgical bottleneck with a simple fluid test are staggering. A diagnosis that takes weeks instead of years means patients can access specialized pain management, pelvic floor physical therapy, and fertility preservation much earlier in their lives. It also validates the patient's experience, providing a definitive medical answer that ends years of psychological distress and medical gaslighting.[4][6]

Despite the immense promise, systemic barriers to widespread implementation remain. The primary hurdle is accessibility and cost. Advanced genomic sequencing and AI modeling are expensive, and until these tests secure broad insurance coverage and integration into national health systems, they risk becoming a luxury available only to those who can pay out of pocket. Furthermore, while liquid biopsies can confirm the presence of the disease, surgery remains necessary for patients who require the physical removal of painful lesions or cysts.[1][3]

Nevertheless, the trajectory is clear. As these technologies scale and clinical trials expand, the cost of sequencing will inevitably drop. The convergence of artificial intelligence, proteomics, and women's health advocacy has pushed endometriosis out of the shadows and into the forefront of precision medicine. For the millions of women navigating the healthcare system today, the era of the ten-year diagnostic delay is finally coming to an end.[1][6]